Krystal Biotech, Inc. (KRYS)

Nasdaq Biotechnology Diagnostics SIC: 2836

Pipeline Grade

Financial Position (from SEC Filings)

$501.3M

Cash & Equivalents

$80.4M

Quarterly Burn Rate

$10,784M

Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.

NCT #	Title	Phase	Status	Enrollment
NCT06563414	A Natural History Study of Corneal Abrasions in Patients With Dystrophic Epidermolysis Bullosa (DEB)	OTHER	Recruiting	40
NCT04917887	Long-Term Follow-up Protocol	OTHER	Recruiting	50
NCT07016750	A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis Bullosa	PHASE3	Recruiting	16
NCT06228326	A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs	PHASE2	Recruiting	250
NCT06724900	A Study Assessing KB304 for the Treatment of Wrinkles in Women	PHASE2	Active Not Recruiting	19
NCT05970497	A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors	PHASE2	Recruiting	240
NCT06999733	A Study Comparing KB801 Verse Placebo in Patients With Stage 2 or 3 Neurotrophic Keratitis	PHASE2	Recruiting	60
NCT06049082	A Study of KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency	PHASE1	Recruiting	15
NCT05504837	A Study Assessing KB407 for the Treatment of Cystic Fibrosis	PHASE1	Recruiting	20
NCT04540900	A Phase I Study of KB301, a Replication-Incompetent, Non-Integrating Vector Expressing Human Type III Collagen (COL3) fo...	PHASE1	Active Not Recruiting	85

Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for KRYS.

All SEC filings for Krystal Biotech, Inc. on EDGAR.

View all upcoming FDA catalysts across all biotech companies.